JNP
Income statement / Annual
Last year (2017), Juniper Pharmaceuticals, Inc.'s total revenue was $49.98 M,
a decrease of 8.42% from the previous year.
In 2017, Juniper Pharmaceuticals, Inc.'s net income was -$2.06 M.
See Juniper Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
FY-2010
|
FY-2009
|
FY-2008
|
| Period Ended |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
12/31/2010 |
12/31/2009 |
12/31/2008 |
| Operating Revenue |
$49.98 M |
$54.57 M |
$37.56 M |
$32.46 M |
$29.23 M |
$25.83 M |
$43.06 M |
$45.68 M |
$32.20 M |
$36.34 M |
| Cost of Revenue |
$28.96 M
|
$24.29 M
|
$21.41 M
|
$17.69 M
|
$13.25 M
|
$12.79 M
|
$11.69 M
|
$9.02 M
|
$9.19 M
|
$10.93 M
|
| Gross Profit |
$21.02 M
|
$30.28 M
|
$16.14 M
|
$14.78 M
|
$15.98 M
|
$13.04 M
|
$31.37 M
|
$36.66 M
|
$23.00 M
|
$25.41 M
|
| Gross Profit Ratio |
0.42
|
0.55
|
0.43
|
0.46
|
0.55
|
0.5
|
0.73
|
0.8
|
0.71
|
0.7
|
| Research and Development Expenses |
$6.86 M
|
$9.68 M
|
$6.95 M
|
$663.00 K
|
$0.00
|
$770.64 K
|
$2.78 M
|
$8.58 M
|
$8.58 M
|
$6.21 M
|
| General & Administrative Expenses |
$15.39 M
|
$14.07 M
|
$10.46 M
|
$8.59 M
|
$8.04 M
|
$8.57 M
|
$8.11 M
|
$14.72 M
|
$10.56 M
|
$0.00
|
| Selling & Marketing Expenses |
$1.86 M
|
$1.26 M
|
$1.25 M
|
$1.71 M
|
$438.95 K
|
$0.00
|
$87.67 K
|
$9.66 M
|
$11.98 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.24 M
|
$15.33 M
|
$11.71 M
|
$10.30 M
|
$8.48 M
|
$8.57 M
|
$8.20 M
|
$24.38 M
|
$22.54 M
|
$21.41 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$24.10 M
|
$25.00 M
|
$18.66 M
|
$10.96 M
|
$8.48 M
|
$9.34 M
|
$10.97 M
|
$35.48 M
|
$36.17 M
|
$32.66 M
|
| Cost And Expenses |
$53.07 M
|
$49.29 M
|
$40.07 M
|
$28.65 M
|
$21.73 M
|
$22.13 M
|
$22.67 M
|
$44.50 M
|
$45.36 M
|
$43.60 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$71.28 K
|
$238.03 K
|
$107.26 K
|
$28.84 K
|
$33.83 K
|
$299.81 K
|
| Interest Expense |
$130.00 K
|
$97.00 K
|
$106.00 K
|
$118.00 K
|
$0.00
|
$0.00
|
$12.11 K
|
$4.84 M
|
$8.85 M
|
$7.88 M
|
| Depreciation & Amortization |
-$970.00 K
|
$1.90 M
|
-$488.00 K
|
$1.99 M
|
$919.10 K
|
$642.36 K
|
-$2.43 M
|
$3.16 M
|
$5.04 M
|
$8.07 M
|
| EBITDA |
-$3.09 M |
$5.28 M |
-$2.51 M |
$3.82 M |
$8.42 M |
$10.56 M |
$20.58 M |
$4.36 M |
-$8.08 M |
$812.21 K |
| EBITDA Ratio |
-0.06
|
0.1
|
-0.07
|
0.12
|
0.29
|
0.41
|
0.48
|
0.1
|
-0.25
|
0.02
|
| Operating Income Ratio |
-0.06
|
0.05
|
-0.07
|
0.04
|
0.29
|
0.11
|
0.53
|
0.03
|
-0.41
|
-0.2
|
| Total Other Income/Expenses Net |
$840.00 K
|
$3.52 M
|
$382.00 K
|
$3.24 M
|
-$1.62 M
|
$7.11 M
|
-$2.36 M
|
-$23.48 M
|
-$9.06 M
|
-$7.68 M
|
| Income Before Tax |
-$2.25 M
|
$6.04 M
|
-$2.13 M
|
$4.38 M
|
$6.73 M
|
$9.92 M
|
$20.57 M
|
-$22.31 M
|
-$22.22 M
|
-$14.94 M
|
| Income Before Tax Ratio |
-0.04
|
0.11
|
-0.06
|
0.13
|
0.23
|
0.38
|
0.48
|
-0.49
|
-0.69
|
-0.41
|
| Income Tax Expense |
-$186.00 K
|
$91.00 K
|
$5.00 K
|
$988.00 K
|
$22.56 K
|
$2.71 K
|
$39.28 K
|
-$475.42 K
|
-$355.03 K
|
-$863.77 K
|
| Net Income |
-$2.06 M
|
$5.95 M
|
-$2.13 M
|
$3.39 M
|
$6.70 M
|
$9.92 M
|
$20.53 M
|
-$21.83 M
|
-$21.87 M
|
-$14.08 M
|
| Net Income Ratio |
-0.04
|
0.11
|
-0.06
|
0.1
|
0.23
|
0.38
|
0.48
|
-0.48
|
-0.68
|
-0.39
|
| EPS |
-0.19 |
0.55 |
-0.2 |
0.31 |
0.59 |
0.88 |
1.92 |
-2.38 |
-3.1 |
-2.15 |
| EPS Diluted |
-0.19 |
0.55 |
-0.2 |
0.27 |
0.52 |
0.24 |
1.76 |
-2.38 |
-3.1 |
-2.15 |
| Weighted Average Shares Out |
$10.82 M
|
$10.80 M
|
$10.77 M
|
$10.99 M
|
$11.26 M
|
$10.91 M
|
$10.79 M
|
$9.18 M
|
$7.04 M
|
$6.55 M
|
| Weighted Average Shares Out Diluted |
$10.82 M
|
$10.89 M
|
$10.77 M
|
$11.01 M
|
$11.27 M
|
$11.06 M
|
$11.57 M
|
$9.18 M
|
$7.04 M
|
$6.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
